Glucos Fresenius Kabi (Glucose Monohydrate)

Glucos Fresenius Kabi is indicated for several clinical situations where rapid glucose supplementation or fluid replacement is required.

• Parenteral nutrition to meet caloric needs when oral intake is insufficient.
• Treatment of hypoglycemia in patients unable to receive oral glucose.
• As a component of balanced electrolyte solutions for fluid resuscitation.
• Support during peri‑operative fasting to maintain plasma glucose levels.
• Adjunct in drug dilution for compatible intravenous medications.

When administered intravenously, Glucos Fresenius Kabi may be associated with a range of observed effects, most of which are related to the glucose load and the infusion process.

Common

• Transient hyperglycemia.
• Local irritation or phlebitis at the infusion site.
• Fluid overload in susceptible patients.
• Mild electrolyte disturbances such as hyponatremia.
• Nausea or mild headache.
• Transient increase in serum osmolality.

Serious

• Severe hyperglycemia leading to ketoacidosis.
• Anaphylactic or severe allergic reaction.
• Hyperosmolar coma.
• Severe fluid overload causing pulmonary edema.
• Metabolic acidosis.
• Life‑threatening electrolyte imbalance.

Clinicians should consider several precautionary measures before and during the use of Glucos Fresenius Kabi to minimize risks.

• Verify the patient’s baseline blood glucose and electrolyte levels prior to infusion.
• Adjust infusion rate in individuals with renal or cardiac impairment.
• Avoid rapid large‑volume administration in neonates and infants.
• Monitor for signs of fluid overload, especially in patients with heart failure.
• Use aseptic technique to prevent catheter‑related infections.
• Assess compatibility with other IV drugs before mixing.
• Consider the patient’s nutritional status and total caloric intake.

Glucose solutions can interact with other intravenous agents or patient conditions, influencing safety and efficacy.

Avoid

• Co‑administration with other hypertonic dextrose solutions that could precipitate severe hyperglycemia.
• Mixing with calcium‑containing solutions that may cause precipitation.
• Use with insulin infusions without appropriate glucose monitoring.

Use with caution

• Concurrent diuretics that may exacerbate electrolyte shifts.
• Patients receiving beta‑blockers, as hypoglycemia symptoms may be masked.
• Additional parenteral nutrition formulations to avoid excessive caloric load.
• Vasopressors that may affect peripheral perfusion at the infusion site.
• Medications that require strict glycemic control, such as certain chemotherapeutics.